Zenas BioPharma, Inc. ZBIO
27.64 USD -1.06 (-3.69%)
At closeNov 12, 2026, 5:15 PM EST
26.60 -1.04 -3.76%
After hours · Nov 12, 5:15 PM ET
27.42 Day range 28.75
13.50 52-week range 44.60
- YTD
- -23.88%
- 1 year
- -22.79%
News
defenseworld.net Zenas BioPharma, Inc. $ZBIO Shares Acquired by Alps Advisors Inc. Alps Advisors Inc. increased its position in shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) by 35.6% during the undefined quarter, according to its most recent disclosure with the Securities and…
globenewswire.com Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the…
benzinga.com Zenas BioPharma Q3 EPS $(1.65) Misses $(1.33) Estimate, Sales $10.000M Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(1.33) by 24.06 percent. This is a 35.25 percent decrease over losses of…
globenewswire.com Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update - PDUFA target action date of May 27, 2027, following FDA acceptance of obexelimab BLA submission for the treatment of IgG4-RD in August 2026 - - Obexelimab MAA submitted to the EMA for the treatment…
defenseworld.net Head-To-Head Review: BioCryst Pharmaceuticals (NASDAQ:BCRX) & Zenas BioPharma (NASDAQ:ZBIO) BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two…
marketbeat.com Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears Zenas BioPharma NASDAQ: ZBIO outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of…
seekingalpha.com Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript
zacks.com Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know The mean of analysts' price targets for Zenas BioPharma, Inc. (ZBIO) points to a 77.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
globenewswire.com Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the…
benzinga.com HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.- benzinga.com Zenas BioPharma Presents New Obexelimab Data In Immunoglobulin G4-Related Disease At 6th International Symposium On IgG4-Related Disease – Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab –– Additional analyses of secondary endpoints showed that significantly fewer patients…
globenewswire.com Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026 WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients…
globenewswire.com Zenas BioPharma to Host Virtual R&D Event WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the…
seekingalpha.com Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve Zenas BioPharma (ZBIO) is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date, positioning as a long-term maintenance therapy. ZBIO maintains a sizable cash runway, with…
benzinga.com Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48 Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $41 to $48.- benzinga.com Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
seekingalpha.com Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
benzinga.com Zenas BioPharma To Present New Data From Phase 3 INDIGO Trial Evaluating Obexelimab In IgG4-RD At 6th International Symposium On IgG4-Related Disease, And ACR Convergence 2026 – New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –– Additional analyses will assess…
globenewswire.com Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 – New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –
globenewswire.com Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in…
seekingalpha.com Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
benzinga.com Zenas BioPharma Registers Resale Of Up To 7M Shares By Selling Stocholder ZENAS BIOPHARMA, INC.Up to 7,000,000 Shares of Common StockThis prospectus relates to the resale or other disposition from time to time of up to 7,000,000 shares (the "Shares") of our common stock,…
defenseworld.net Analyzing United Therapeutics (NASDAQ:UTHR) and Zenas BioPharma (NASDAQ:ZBIO) United Therapeutics (NASDAQ: UTHR - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two…
seekingalpha.com Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
globenewswire.com Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in…
globenewswire.com Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in…
defenseworld.net Bank of America Corp DE Purchases 341,187 Shares of Zenas BioPharma, Inc. $ZBIO Bank of America Corp DE boosted its position in shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) by 723.5% during the first quarter, according to its most recent disclosure with the Securities and…
benzinga.com Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32 Morgan Stanley analyst Judah Frommer maintains Zenas BioPharma (NASDAQ:ZBIO) with a Equal-Weight and raises the price target from $22 to $32.
benzinga.com Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $55 price target.- benzinga.com Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.
benzinga.com Zenas BioPharma Q2 EPS $(1.77) Misses $(1.08) Estimate, Sales $1.000M Miss $18.750M Estimate Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.08) by 63.89 percent. This is a 41.6 percent decrease over losses of…
benzinga.com Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results. Other stocks declining in pre-market trading.
benzinga.com Earnings Scheduled For May 13, 2026 
benzinga.com Alpha Buying: Insider Conviction in High-Risk Biotech 
benzinga.com Crude Oil Surges 4%; US Consumer Sentiment Declines In March U.S. stocks down, NASDAQ drops 1.5% on Friday. Energy shares up, consumer discretionary down. University of Michigan's Consumer Sentiment Index falls.
benzinga.com Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of public offerings. Other stocks also lower.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why Newsmax Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket Newsmax Inc (NMAX) shares rose on better-than-expected Q4 results & FY26 sales guidance. Pre-market gainers include ONCO, VSA, GMEX, IZM, GVH, BATL, U, SGML, & GLND. Losers are SLND, DTCX, TOP, SVRN,…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday 
benzinga.com Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Jefferson Capital, Mobix Labs And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session